Table 2.

Pre- and post-vaccination antibody concentrations to seven serotypes included in the 7-valent pneumococcal conjugate vaccine (PCV7, bold) and two serotypes included in the 23-valent pneumococcal polysaccharide vaccine (PPV23) in patients with CLL and in controls.

	Pre-vaccination antibody concentration GMC (μg/ml) (quartiles)		Post-vaccination antibody concentration GMC (μg/ml) (quartiles)a
Serotype	CLL (n = 20)	Control (n = 8)	CLL (n = 20)	Control (n = 8)	p-valuea
4	0.12 (0.02–0.40)	0.34 (0.13–0.90)	0.13 (0.02–0.67)	1.96 (1.36–2.82)	<0.001
5	0.16 (0.08–0.44)	0.15 (0.08–0.25)	0.22 (0.08–0.64)	2.20 (0.53–5.57)	0.002
6B	0.46 (0.11–1.69)	0.30 (0.06–1.24	0.56 (0.14–3.39)	2.28 (0.75–9.96)	0.063
7F	0.38 (0.07–1.27)	0.56 (0.31–1.23)	0.55 (0.07–1.83)	6.74 (2.97–13.8)	<0.001
9V	0.51 (0.23–2.33)	0.91 (0.17–5.06)	0.62 (0.32–2.29)	3.04 (0.58–12.1)	0.033
14	0.77 (0.20–4.14)	1.56 (0.45–5.83)	0.96 (0.17–6.20)	6.65 (3.00–24.0)	0.021
18C	0.93 (0.26–3.06)	1.55 (1.00–2.47)	1.06 (0.27–4.07)	6.81 (3.82–15.7)	0.010
19F	0.97 (0.30–2.88)	0.83 (0.31–1.56)	1.29 (0.33–4.20)	4.18 (1.88–6.05)	0.055
23F	0.53 (0.14–1.56)	0.82 (0.25–2.23	0.67 (0.13–4.41)	2.29 (2.07–3.32)	0.150

^aBetween post-vaccination concentrations in patients with CLL and controls

^aIndependent-samples Mann–Whitney U-test (statistical significance if p ≤ .05)